İsteğe bağlı ürün analizi
İzninizle, hangi araştırma yolculuklarının işe yaradığını anlamak için gizliliği gözeten sınırlı analizler kullanırız. Reklam izleyicileri veya oturum kaydı kullanmayız. Bu seçimi Tercihler bölümünden değiştirebilirsiniz. Okuyun Gizlilik Politikası.
Microchip Technology Incorporated's published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $41.2B | |
|---|---|---|
| Revenue (ttm) | 5.1B | |
| Net income (ttm) | 367.2M | |
| EPS (ttm) | $0.68 | |
| Shares out | 543M | |
| P/E (trailing) | 117.4x | |
| P/E (forward) | 20.5x | |
| Dividend | $1.82 (2.30%) | |
| Volume | 6,184,831 | |
| Beta | 1.76 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 | Trend |
| Revenue | $6.82B | $8.44B | $7.63B | $4.40B | $4.71B | -8.8% |
| Gross profit | $4.45B | $5.70B | $5.00B | $2.47B | $2.72B | -11.6% |
| Operating income | $1.85B | $3.12B | $2.57B | $296.3M | $490.1M | -28.3% |
| Net income | $1.29B | $2.24B | $1.91B | $-500.0K | $230.0M | -35.0% |
| EPS (diluted) | $2.27 | $4.02 | $3.48 | $-0.01 | $0.22 | -44.2% |
| EBITDA | $2.87B | $4.10B | $3.44B | $1.04B | $1.40B | -16.4% |
| R&D | $989.1M | $1.12B | $1.10B | $983.8M | $1.09B | +2.4% |
| SG&A | $718.9M | $797.7M | $734.2M | $617.7M | $674.3M | -1.6% |
Recent company headlines from major financial publishers.
In the bull scenario, industrial automation and automotive demand experience a synchronized cyclical rebound, while data center AI connectivity design wins ramp faster than planned. Book-to-bill sustains comfortably above 1.1x, enabling fab utilization to exceed 85% and driving operating margins toward 38%. Under these conditions, FY2028 revenue accelerates beyond $8.39B and diluted EPS reaches the upper analyst consensus range of $5.44,.
The base scenario reflects the house forecast schedule where net sales recover +35.6% in FY2027 to $6,391.0M and +16.1% in FY2028 to $7,419.9M, tracking analyst consensus estimates,. Operating margins expand from 10.40% in FY2026 to 25.0% in FY2027 and 32.5% in FY2028, yielding diluted EPS of $3.65 and $4.58 respectively,. Capital reinvestment is maintained at 12% of NOPAT based on capex guidance of $100M and long-term tax rate remains at 19.04%.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 10.8% | $55.3 | $56.1 | $57.0 | $57.9 | $58.9 |
| 11.3% | $52.9 | $53.5 | $54.3 | $55.1 | $55.9 |
| 11.8% | $50.6 | $51.2 | $51.8 | $52.5 | $53.2 |
| 12.3% | $48.6 | $49.1 | $49.6 | $50.2 | $50.9 |
| 12.8% | $46.7 | $47.1 | $47.6 | $48.2 | $48.7 |
Upcoming earnings date and setup when available.
Her ay yayımlanan araştırma sürümünün taşıdığı derecelendirme. Bir derecelendirme, analiz tarihindeki fiyatı gerçeğe uygun değerle karşılaştırır; tahminin doğru çıkıp çıkmadığının kaydı değildir.
| Yıl | Oca | Şub | Mar | Nis | May | Haz | Tem | Ağu | Eyl | Eki | Kas | Ara |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |